Brainsway* is dedicated to developing and providing advanced technology solutions for the treatment of a variety of brain disorders. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. Brainsway's flagship technology is Deep TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment.
Brainsway's Transcranial Magnetic Stimulation technology is based on patents filed by the U.S. National Institutes of Health (NIH), and by the company. The company holds an exclusive license from the NIH for the patent and for Deep TMS technology.
Brainsway's Deep TMS is FDA cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288).
Brainsway runs clinical research programs with leading scientists worldwide, collaborating with prominent institutions and researchers in clinical trials covering various neuropsychiatric and neuroscience applications.
The company's Transcranial Magnetic Stimulation technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials held across the globe.
* Brainsway and the Brainsway logo are trademarks of Brainsway Ltd.